Evaluation of clinical and microbiological factors related to mortality in patients with Gram-negative bacterial infections treated with ceftazidime–avibactam: A prospective multicentric cohort study

This publication has 18 references indexed in Scilit:

• Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients
  International Journal of Antimicrobial Agents, 2019
• Evaluation of the efficacy and safety of ceftazidime/avibactam in the treatment of Gram-negative bacterial infections: a systematic review and meta-analysis
  International Journal of Antimicrobial Agents, 2018
• Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime–avibactam
  Infection and Drug Resistance, 2018
• Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused byKlebsiella pneumoniaeCarbapenemase–producingK. pneumoniae
  Clinical Infectious Diseases, 2018
• Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections
  Antimicrobial Agents and Chemotherapy, 2018
• AmpC β-lactamase induction by avibactam and relebactam
  Journal of Antimicrobial Chemotherapy, 2017
• Antimicrobial Resistance
  JAMA, 2016
• Impact of antimicrobial multidrug resistance on inpatient care cost: an evaluation of the evidence
  Expert Review of Anti-infective Therapy, 2013
• A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation
  Journal of Chronic Diseases, 1987
• APACHE II
  Critical Care Medicine, 1985